Nealanders to Feature Allegiance`s Revolutionary CinGX at Supply Side West, the World's Largest Event for Healthy and Innovat...
15 Septembre 2011 - 8:51PM
PR Newswire (Canada)
TORONTO, Sept. 15, 2011 /CNW/ -- TORONTO, Sept. 15, 2011 /CNW/ -
Allegiance Equity Corporation (TSXV:ANQ.V) is pleased to announce
that Nealanders will feature Allegiance's proprietary CinGx
revolutionary additive at the Supply Side West Event. Nealanders
International - a world-class supplier of ingredients and additives
in the food industry, the exclusive distributor of CinGx(TM) in
North America; will introduce CinGx at Supply Side West to be held
in Las Vegas October 10(th) - 14(th). ABOUT CING-X Allegiance
Equity Corporation recently developed CinGx, a unique product to
treat and prevent Type 3 Diabetes resulting from the impact of
Diabetes on brain function. CinGx is a formula combining two
extracts which act synergistically to control glucose metabolism,
improve cognitive function and simultaneously minimize the risk of
developing and treating CVD, diabetes, dementia and Alzheimer's.
CinGx is a proprietary additive that enhances the value of any
food, beverage or nutritional supplement and can be combined with
most other ingredients. Products with CinGx to date include
chocolate snacks, yogurt and beverages. Recent research
discovered that the brain produces insulin and depriving brain
cells of insulin damages the cells, leading to memory loss,
dementia, and Alzheimer's Disease. The impact of high blood glucose
levels results in Type 3 Diabetes, also known as "brain diabetes."
CinGx(TM) will greatly benefit the rapidly increasing number of
North Americans diagnosed with diabetes, particularly Type 3
Diabetes. "Diabetes is one of the clear metabolic risk factors for
Alzheimer's Disease (AD), perhaps through insulin signaling or
secondary cardiovascular effects," says Dr. Cantillon, American
Board Certified Neurologist and Psychiatrist. "After rosiglitazone
and other failures, there are no metabolic treatments in sight for
AD that are effective and/or do not have serious side effects.
Therefore, insulin receptor protein tyrosine kinase treatment for
Type 3 Diabetes might represent a new opportunity for long term
safe prevention of Alzheimer's. "We are extremely fortunate and
grateful to have Nealanders as a partner, you couldn't have asked
for a better fit for Allegiance. They are poised to market
CinGx(TM) to their clients for placement in a variety of foods and
beverages", stated David Solomon, President of Allegiance.
Nealanders has completed regulatory documentation for compliance
with Health Canada and the FDA requirements to facilitate marketing
CinGx(TM) to its clients. They have formulated foods and beverages
in several categories containing CinGx(TM) for presentation where
Nealanders has established relationships and rapport with key
Marketing and Sales, as well as Product Development personnel. "I
am very excited about moving forward with this revolutionary new
additive, says Steve Owen, VP Sourcing, Product Development &
GM - Ontario. With the added value CinGx(TM) brings to our
customers' products and the important health benefits for
consumers". ABOUT NEALANDERS Nealanders is recognized as the leader
in the manufacturing and distribution of food ingredients,
specializing in antioxidants, release agents, dough conditioners
and enrichment blends. Proudly Canadian, Nealanders' Head Office is
located in Mississauga, Ontario, with facilities strategically
located across North America providing their customers with
coast-to-coast coverage in both distribution and technical sales.
On the leading edge of emerging trends and a strategic focus on
wellness. Nealanders has extensive laboratory capabilities for
product development and full technical and regulatory support.
Nealanders embraces a customer focused mindset and value creation
for their customers. ABOUT ALLEGIANCE Allegiance targets billion
dollar markets having clearly identified product deficiencies and
dissatisfied patients who suffer widespread diseases and conditions
including diabetes, cholesterol, Alzheimer`s and Dementia and
arthritis. Allegiance's strategy utilizes leading-edge scientific
technology to create valuable, proprietary and effective natural
treatments, recognized as safe and effective by North American
regulatory authorities, at a fraction of the cost and time it takes
to develop a prescription drug. Allegiance then obtains patents and
regulatory approvals. Additional information relevant to the
Company's activities, including the Company's press releases can be
found on SEDAR at www.sedar.com. The TSX Venture Exchange has not
reviewed and does not accept responsibility FOR THE ADEQUACY OR
ACCURACY FOR THIS PRESS RELEASE, WHICH HAS BEEN PREPARED BY
MANAGEMENT. To view this news release in HTML formatting, please
use the following URL:
http://www.newswire.ca/en/releases/archive/September2011/15/c3786.html
p Allegiance Equity Corporationbr/ David Solomonbr/ Presidentbr/
(416) 630 1221br/ Email a
href="mailto:dsolomon79@gmail.com"dsolomon79@gmail.com/a /p
Copyright
(TSXV:ANQ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(TSXV:ANQ)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about (TSX Venture Exchange): 0 recent articles
Plus d'articles sur Allegiance Equity Corp